Diadema Partners LP Purchases Shares of 698,919 Nektar Therapeutics (NASDAQ:NKTR)

Diadema Partners LP bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 698,919 shares of the biopharmaceutical company's stock, valued at approximately $650,000. Diadema Partners LP owned approximately 0.38% of Nektar Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in Nektar Therapeutics in the third quarter worth about $46,000. Moloney Securities Asset Management LLC increased its position in Nektar Therapeutics by 42.4% during the 4th quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company's stock valued at $46,000 after buying an additional 14,895 shares in the last quarter. HB Wealth Management LLC raised its stake in Nektar Therapeutics by 44.0% during the fourth quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company's stock valued at $60,000 after buying an additional 19,600 shares during the last quarter. Sei Investments Co. boosted its holdings in Nektar Therapeutics by 50.6% in the fourth quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 31,654 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in shares of Nektar Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company's stock worth $100,000 after acquiring an additional 11,681 shares during the last quarter. 75.88% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Stock Up 5.0 %

NASDAQ:NKTR traded up $0.04 on Friday, hitting $0.78. The stock had a trading volume of 3,162,228 shares, compared to its average volume of 1,812,019. The business's 50-day simple moving average is $0.74 and its two-hundred day simple moving average is $0.95. The stock has a market cap of $144.25 million, a price-to-earnings ratio of -0.92 and a beta of 0.69. Nektar Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.33. The company had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. As a group, equities research analysts anticipate that Nektar Therapeutics will post -0.72 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on NKTR shares. B. Riley assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price objective on the stock. William Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research report on Thursday, March 13th. HC Wainwright reaffirmed a "buy" rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their price target for the stock from $1.00 to $2.00 in a research note on Friday, April 11th. Finally, Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price objective on the stock in a research report on Friday, March 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $4.50.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.